Seelos therapeutics announces the selection of sls-002 (intranasal racemic ketamine) for inclusion in the u.s. department of defense's adaptive platform trial to evaluate potential treatments for post-traumatic stress disorder (ptsd)

- the ptsd-drug treatment program is funded by the u.s. department of defense's defense health agency new york , nov. 27, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that sls-002 (intranasal racemic ketamine) has been selected for inclusion in an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (ptsd) in active-duty service members and veterans. the trial is funded by the u.s. department of defense's (dod) defense health agency and led by the warfighter readiness, performance, and brain health project management office, part of the u.s. army medical materiel development activity.
SEEL Ratings Summary
SEEL Quant Ranking